IBM has fallen out of its Tech leadership role over the years. 25 years ago it ranked as the seventh largest stock in the S&P 500, but today it is only the 40th largest.

GE HealthCare (Nasdaq: GEHC) today announced a $138 million investment to expand its Carrigtohill, Cork contrast media fill and finish manufacturing site in Ireland. A new state-of-the-art facility on the grounds of the existing site will enable 25 million more patient doses per year of contrast media by the end of 2027, helping address growing global demand.

GE HealthCare (Nasdaq: GEHC) has been named to 2025 Fortune World’s Most Admired Companies™ list. The company has been recognized across several categories including the quality of management, products and services, innovation, value as a long-term investment, financial soundness, talent acquisition and retention, community and environmental responsibility, global business, and use of corporate assets.

GE HealthCare (Nasdaq: GEHC) today announced it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for the updated portfolio of Voluson™ Expert Series ultrasound systems. Voluson Expert 22, 20 and 18 combine high resolution image quality with advanced ultrasound technology and an ergonomic design for efficient workflow and a world-class user experience. The Voluson Expert Series integrates artificial intelligence (AI)-powered features and automation tools to help drive imaging performance and efficiencies in women’s healthcare.

See which three big-name U.S. stocks have announced new buyback programs as the first earnings season of 2025 kicks into gear.

GLP-1 drugs have been all the rage for weight loss, but GE Healthcare and Novo Nordisk are working on a non-invasive approach to controlling metabolic functions

Analysts assessed President Trump's impact on its wind unit.

University of California, San Francisco (UCSF) Department of Radiology & Biomedical Imaging and GE HealthCare today announced the launch of a Care Innovation Hub, a joint research collaboration that aims to address meaningful clinical challenges in three key areas: accessibility to advanced medical imaging, non-invasive diagnosis and management of neurological and neurodegenerative disease, and precision oncology. The Care Innovation Hub leverages the strengths of academia and industry to create, evaluate and translate novel technology into a clinical setting with the goals of advancing diagnosis and treatment of disease, improving hospital operations and driving more equitable access to care.

Sutter Health and GE HealthCare (Nasdaq: GEHC) today announced a seven-year strategic enterprise partnership, known as a Care Alliance, that aims to increase access to innovative imaging services and create a more seamless and coordinated experience for clinicians and patients across the Sutter Health system. The long-term collaboration will increase access to essential diagnostic care across California, providing patients with advanced technology in their own communities that can help enable quicker appointment scheduling, accelerated diagnostic imaging scan results, early diagnoses, greater convenience, and more consistent and timely care. This Care Alliance marks one of GE HealthCare's largest ever enterprise strategic partnerships.

Shares of GE HealthCare Technologies are trading higher because of an upgrade. There has been resistance around $94.

Since the spin-off on March 27, GEV is the second best performing stock in the S&P 500 with a 161.9% gain.

GE Vernova's gas-powered turbines will be key for big tech companies looking to power data center campuses.

GE HealthCare (Nasdaq: GEHC) will announce its fourth quarter and full year 2024 financial results before the market opens on Thursday, February 13, 2025. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website.

Good news: You were right to buy GE Aerospace stock in 2024. Bad news: The next few years probably won't be so great.

GE HealthCare (Nasdaq: GEHC) unveiled three new advanced deep learning image processing and reconstruction solutions as a part of its Effortless Recon DL portfolio at the Radiological Society of North America (RSNA) 2024 Annual Meeting, in Chicago, IL. Understanding the need to improve operational efficiencies within radiology departments and the ongoing challenge of burnout experienced by clinicians, GE HealthCare developed the technologies to deliver exceptional image quality, reduce scan times, and support improved patient outcomes.

As part of a companywide commitment to advance innovation that improves the health of patients and the planet, GE HealthCare (Nasdaq: GEHC) is highlighting several solutions with increased focus on sustainability at the Radiological Society of North America (RSNA) 2024 Annual Meeting, which is held Dec. 1-4 in Chicago, IL.

GE HealthCare (Nasdaq: GEHC) announced today the 510(k) submission to the U.S. Food and Drug Administration for CleaRecon DL, deep learning technology, designed to improve the quality of cone-beam computed tomography (CBCT) images by bringing artificial intelligence (AI)-based 3D reconstruction to the interventional suite. This technology, which is pending 510(k) clearance, will be demonstrated at the Radiological Society of North America’s (RSNA) 2024 Annual Meeting taking place from December 1-4 in Chicago.

GE HealthCare (Nasdaq: GEHC) has agreed to acquire full ownership of Nihon Medi-Physics Co., Ltd (NMP), by purchasing from Sumitomo Chemical (TYO: 4005) the 50% stake it does not already own. As part of GE HealthCare, NMP can build on its expertise developing and manufacturing proprietary and in-licensed radiopharmaceuticals used in single photon emission computed tomography (SPECT) and positron emission tomography (PET) molecular imaging procedures to detect and diagnose disease. Sumitomo and GE HealthCare expect the agreement to close in early 2025, subject to regulatory approvals.

GE HealthCare (Nasdaq: GEHC) today unveiled Sonic DL for 3Dii, the newest addition to its effortless imaging portfolio, designed to accelerate MRI scans across a wide range of clinical applications. Sonic DL for 3D builds on GE HealthCare’s deep learning innovation legacy and the success of AIR Recon DL, which has helped over 34 million patients to date. Initially launched in 2023 for Cardiac MRI, Sonic DL provides up to 12 times scan acceleration while maintaining diagnostic qualityiii. Now, GE HealthCare is extending Sonic DL to 3D volumetric imaging, designing it to broaden its applicability to brain, spine, orthopedic and body exams, in addition to cardiac. This expansion is intended to retain the same impressive 12x acceleration and reduce scan times by up to 86%.